Special Issue

Vaccination and Virus Epidemic Control

Message from the Guest Editors

The recent COVID-19 pandemic highlighted the importance of achieving rapid research advance to control virus epidemics. Vaccination is the main pharmaceutical intervention to contain an epidemic and to protect the population against the transmission of infection. On the epidemiological and clinical level. vaccines face challenges in terms of reducing the spread of the infection, inducing immunity, and reducing the morbidity/mortality of the infection-induced disease. Those factors include vaccine acceptability, risk perception, and vaccine hesitancy among a part of the population. We are pleased to invite you to submit articles on the efficacy, safety, and duration of immunity induced by vaccines as well as on the clinical impact of vaccination in terms of reducing virus infections and severity of diseases. Other valued contributions regard learning and communication programs to raise the vaccination uptake, interventions to improve the readability of official educational documents, and analyses to assess vaccine literacy.

Guest Editors

Dr. Antonella Zizza

Dr. Virginia Recchia

Dr. Pierfrancesco Grima

Deadline for manuscript submissions

closed (30 June 2023)



an Open Access Journal by MDPI

Impact Factor 5.2 CiteScore 8.9 Indexed in PubMed



mdpi.com/si/102867

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/ vaccines





an Open Access Journal by MDPI

Impact Factor 5.2 CiteScore 8.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).

